Concepedia

Anthony D.R. Angell

AD

Statistics

Publications

4

Citations

235

H-Index

4

Active since

1983

Affiliations

GlaxoSmithKline (Croatia)(Current)

Anthony D.R. Angell is an author at GlaxoSmithKline (Croatia) specializing in oxidative stress, medicine, and pharmacology.

Top concepts

Publications per year

1983–2011

4

Publications

4

GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase <i>in vitro</i> and <i>in vivo</i>

W. Alderton, Anthony D.R. Angell, Caroline Craig et al. · British Journal of Pharmacology · 2005 · 88 citations · Full text

GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization

Cathy Tralau-Stewart, Richard A. Williamson, Anthony T. Nials et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 69 citations

Impaired mobilisation of cholesterol from stored cholesteryl esters in human (THP-1) macrophages

Annette Graham, Anthony D.R. Angell, Catherine A. Jepson et al. · Atherosclerosis · 1996 · 62 citations

, , +7

Synthesis and release of Hageman factor (Factor XII) by the isolated perfused rat liver.

Hidehiko Saito, S. M. Hamilton, Anthony S. Tavill et al. · Journal of Clinical Investigation · 1983 · 16 citations · Full text

, , +19

1–4 of 4